---
title: "Varegacestat (AL102) in Desmoid tumors: Phase of product development"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Phase of product development. Topics: Regulatory status: Under review; NDA submitted April 2026, PDUFA target action date April 2027; Commercial launch preparation; NDA submission, April 2026; FDA acceptance of the NDA and PDUFA target action date, July 2026; 19 further topics. 23 evidence topics quoted from 19 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/phase-of-product-development"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Phase of product development

<a id="heading-2.1.1"></a>

## 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

### Regulatory status: Under review; NDA submitted April 2026, PDUFA target action date April 2027

> “We acquired varegacestat from Ayala Pharmaceuticals, Inc., or Ayala, in March 2024. We submitted an NDA for varegacestat in April 2026. In July 2026, the FDA accepted the NDA and assigned a PDUFA target action date of April 28, 2027.”

Source: [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)

> “The U.S. FDA accepted the varegacestat NDA in July 2026 and assigned a PDUFA target action date of April 28, 2027.”

Source: [Immunome press release, third quarter 2026 results (2026)](https://investors.immunome.com/immunome-reports-third-quarter-2026-financial-results-and-provides-business-update/)

<a id="topic-2.1.1-2"></a>

### Launch

No evidence found.

<a id="topic-2.1.1-3"></a>

### Commercial launch preparation

> “We continue to advance varegacestat toward approval and launch, with an FDA PDUFA date of April 28, 2027, and recent EMA validation of our MAA.”

Source: [Immunome press release, third quarter 2026 results (2026)](https://investors.immunome.com/immunome-reports-third-quarter-2026-financial-results-and-provides-business-update/)

> “We are currently in the early stages of building our internal sales and marketing capabilities to prepare for the commercialization of varegacestat, if approved, and we have never commercialized a product.”
> “The increase was primarily related to increases in expenses related to commercialization readiness, personnel-related costs including share-based compensation from an increase in headcount to support overall growth, and other professional services expenses.”

Source: [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)

> “Launch Strategy”
> “Become Standard of Care treatment of Desmoid Tumors”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

> “We are prioritizing regulatory, clinical, and operational activities to support a potential commercial launch of varegacestat for the treatment of desmoid tumors, subject to regulatory approval.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

> “We are focused on the regulatory, manufacturing, and commercial readiness activities necessary to position the program for approval and launch.”

Source: [Immunome press release, full year 2025 results (2026)](https://investors.immunome.com/immunome-reports-full-year-2025-financial-results-and-provides-business-update/)

<a id="topic-2.1.1-4"></a>

### NDA submission, April 2026

> “today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors.”
> “The NDA is supported by positive results from the global, randomized, double-blind, placebo-controlled Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors.”

Source: [Immunome press release, NDA submission (2026)](https://investors.immunome.com/immunome-announces-submission-of-new-drug-application-to-u-s-fda-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors/)

<a id="topic-2.1.1-5"></a>

### FDA acceptance of the NDA and PDUFA target action date, July 2026

> “today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 28, 2027.”

Source: [Immunome press release, FDA acceptance of NDA (2026)](https://investors.immunome.com/immunome-announces-u-s-fda-acceptance-of-new-drug-application-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors/)

<a id="topic-2.1.1-6"></a>

### NDA review under conventional FDA procedures and timeline

> “For example, the FDA is reviewing our NDA for varegacestat consistent with its conventional procedures and timeline.”

Source: [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm); [Immunome Form 10-Q, second quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526344636/imnm-20260630.htm)

<a id="topic-2.1.1-7"></a>

### EMA marketing authorization application submitted and validated, October 2026

> “today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. Validation confirms that the application is complete, and the EMA will initiate review under the centralized marketing authorization procedure.”

Source: [Immunome press release, EMA validation of MAA (2026)](https://investors.immunome.com/immunome-announces-ema-validation-of-marketing-authorization-application-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors/)

> “We submitted an MAA with the EMA in October 2026. The EMA has validated the MAA and will initiate review under the centralized marketing authorization procedure.”

Source: [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)

<a id="topic-2.1.1-8"></a>

### FDA orphan drug designation, November 2023

| Field | Quoted record |
| --- | --- |
| Generic name | “varegacestat” |
| Date designated | “11/02/2023” |
| Orphan designation | “Treatment of desmoid tumors” |
| Orphan designation status | “Designated” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “Immunome, Inc.” |

Source: [FDA orphan drug designation record for varegacestat (2023)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=968423)

<a id="topic-2.1.1-9"></a>

### FDA Fast Track designation

> “The FDA has granted Fast Track designation for varegacestat for progressing desmoid tumors.”

Source: [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)

<a id="topic-2.1.1-10"></a>

### EMA orphan designation: company statement of July 2025 for desmoid tumors

> “In November 2023, the FDA granted Orphan Drug Designation to varegacestat for the treatment of desmoid tumors and the EMA granted this designation in July 2025, and we may seek additional Orphan Drug Designations for our other product candidates.”
> “For example, European orphan designation may be removed if varegacestat will not offer significant benefit relative to the authorized product nirogacestat.”

Source: [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)

> “The European Medicines Agency granted Orphan Drug Designation to varegacestat in July 2025. Varegacestat previously received Orphan Drug Designation from the U.S. Food and Drug Administration in November 2023.”

Source: [Immunome press release, second quarter 2025 results (2025)](https://investors.immunome.com/immunome-reports-second-quarter-2025-financial-results-and-provides-business-update/)

<a id="topic-2.1.1-11"></a>

### EMA orphan designation: EMA register entry of 22 August 2025 for soft tissue sarcoma

> “This medicine was designated as an orphan medicine for the treatment of soft tissue sarcoma in the European Union on 22 August 2025.”

Source: [EMA orphan designation EU/3/25/3127 (2025)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3127)

| Field | Quoted record |
| --- | --- |
| Active substance | “varegacestat” |
| Intended use | “Treatment of soft tissue sarcoma” |
| Orphan designation status | “Positive” |
| EU designation number | “EU/3/25/3127” |
| Date of designation | “22/08/2025” |
| Sponsor | “Somerville Development Partners B.V.” |

Source: [EMA orphan designation EU/3/25/3127 (2025)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3127)

<a id="topic-2.1.1-12"></a>

### Development history: Bristol-Myers Squibb phase 1 trial of BMS-986115

> “A Phase 1 dose-escalation clinical trial was conducted by Bristol-Myers Squibb, or BMS, in patients with solid tumors. In this trial, one patient with desmoid fibromatosis was enrolled.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

> “This study was sponsored and funded by Bristol-Myers Squibb.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

<a id="topic-2.1.1-13"></a>

### Development history: Ayala Pharmaceuticals license from Bristol-Myers Squibb and design of RINGSIDE

> “In connection with the Ayala Closing, we assumed the License Agreement dated as of November 29, 2017, with BMS, as amended by that certain First Amendment to License Agreement dated as of May 4, 2020, or the BMS License.”
> “Based on these data and responses demonstrated with other GSIs, Ayala designed a seamless Phase 2/3 study called RINGSIDE to specifically evaluate the activity of varegacestat in participants with progressing desmoid tumors who required therapy.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.1.1-14"></a>

### Development history: acquisition by Immunome from Ayala Pharmaceuticals, March 2024

> “On March 25, 2024, the Company and Ayala Pharmaceuticals, Inc., or Ayala, completed an Asset Purchase Agreement, or the Ayala Purchase Agreement, that was entered into in February 2024, pursuant to which the Company acquired Ayala’s AL101 and varegacestat (then known as AL102) programs and assumed certain liabilities associated with the acquired assets.”
> “Under the Ayala Purchase Agreement, the Company may pay Ayala up to an additional $27.5 million in the aggregate upon the achievement of certain future regulatory and commercial milestone events.”
> “In connection with the closing of the Ayala Purchase Agreement in March 2024, the Company assumed a license agreement, or the BMS License Agreement, with Bristol-Myers Squibb Company, or BMS, pursuant to which the Company obtained a worldwide, non-transferable, royalty-bearing, exclusive, sublicensable, license under certain patent rights and know-how of BMS to research, discover, develop, make, have made, use, sell, offer to sell, export, import and commercialize AL101 and varegacestat and products containing AL101 or varegacestat for all uses including the prevention, treatment or control of any human or animal disease, disorder or condition.”

Source: [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)

<a id="topic-2.1.1-15"></a>

### Development history: Amendment No. 4 to the BMS license, October 2026

> “On October 2, 2026, the Company and BMS entered into Amendment No. 4 to the BMS License Agreement, or the Amendment, and a related stock issuance agreement, or the Stock Issuance Agreement. The Amendment removes the Company’s obligation to make any milestone and royalty payments under the BMS License Agreement and assigned to the Company patent rights related to varegacestat (formerly AL102) and AL101 that were previously licensed to the Company under the BMS License Agreement.”
> “As consideration for the Amendment, the Company paid BMS $20.0 million in cash and issued 4,425,487 shares of the Company's common stock, collectively the Amendment Consideration. The Company has no further milestone, royalty or other payment obligations to BMS under the BMS License Agreement or the Amendment.”

Source: [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)

<a id="topic-2.1.1-16"></a>

### Patent expiry

> “The US composition of matter patent covering varegacestat will expire in 2038, which includes 5 years of expected patent term extension. Patent applications covering varegacestat and various derivatives, if issued, are expected to expire between 2033-2045, absent any patent term extensions or adjustments and without accounting for terminal disclaimers.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.1.1-17"></a>

### No product approved for commercial sale

> “We have no drugs approved for commercial sale and have not generated any revenue from drug sales.”

Source: [Immunome Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)

<a id="topic-2.1.1-18"></a>

### MAA submission planned by the end of 2026, August 2026, superseded in October 2026

> “Immunome plans to submit a Marketing Authorization Application to the European Medicines Agency for varegacestat by the end of 2026.”

Source: [Immunome press release, second quarter 2026 results (2026)](https://investors.immunome.com/immunome-reports-second-quarter-2026-financial-results-and-provides-business-update/)

<a id="topic-2.1.1-19"></a>

### MAA submission planned by the end of 2026, May 2026, superseded in October 2026

> “Immunome plans to submit a Marketing Authorization Application to the European Medicines Agency for varegacestat by the end of 2026.”

Source: [Immunome press release, first quarter 2026 results (2026)](https://investors.immunome.com/immunome-reports-first-quarter-2026-financial-results-and-provides-business-update/)

<a id="topic-2.1.1-20"></a>

### NDA submission planned for the second quarter of 2026, March 2026, superseded in April 2026

> “We are completing the manufacturing, toxicology and pharmacology work required to support an NDA submission, and expect to submit an NDA to the FDA for varegacestat for the treatment of desmoid tumors in the second quarter of 2026.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

> “Immunome plans to submit a New Drug Application to the U.S. Food and Drug Administration for varegacestat in the second quarter of 2026.”

Source: [Immunome press release, full year 2025 results (2026)](https://investors.immunome.com/immunome-reports-full-year-2025-financial-results-and-provides-business-update/)

<a id="topic-2.1.1-21"></a>

### NDA submission planned for the second quarter of 2026, December 2025, superseded in April 2026

> “Based on these data, Immunome plans to submit a New Drug Application to the U.S. Food and Drug Administration in Q2 2026.”

Source: [Immunome press release, RINGSIDE topline results (2025)](https://investors.immunome.com/immunome-announces-positive-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors/)

<a id="topic-2.1.1-22"></a>

### Launch preparation anchored to priority review, December 2025, superseded in August 2026

> “Launch preparation anchored to priority review”

Source: [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)

<a id="topic-2.1.1-23"></a>

### Topline data expected before the end of 2025, November 2025, superseded in December 2025

> “Immunome expects to report topline data for the Phase 3 RINGSIDE Part B study before the end of 2025.”

Source: [Immunome press release, third quarter 2025 results (2025)](https://investors.immunome.com/immunome-reports-third-quarter-2025-financial-results-and-provides-business-update/)

<a id="topic-2.1.1-24"></a>

### Topline data expected in the second half of 2025, January 2025, superseded in December 2025

> “Topline data for Phase 3 RINGSIDE study of varegacestat (formerly known as AL102) expected in second half of 2025.”

Source: [Immunome press release, J.P. Morgan 2025 pipeline update (2025)](https://investors.immunome.com/immunome-provides-pipeline-update-in-advance-of-presentation-at-the-43rd-annual-j-p-morgan-healthcare-conference/)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
